Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | GBIO | Common Stock | 92.9K | Sep 16, 2022 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 6.75K | $4.59 | Direct | F1 | ||||||
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 21.4K | $5.16 | Direct | F2 | ||||||
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 31.1K | $5.16 | Direct | F3 | ||||||
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 22K | $30.25 | Direct | F4 | ||||||
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 5.5K | $29.38 | Direct | F5 | ||||||
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 30K | $35.66 | Direct | F6 | ||||||
holding | GBIO | Stock Option (right to buy) | Sep 16, 2022 | Common Stock | 58.7K | $6.49 | Direct | F7 | ||||||
holding | GBIO | Restricted Stock Units | Sep 16, 2022 | Common Stock | 24.8K | Direct | F8, F9 |
Id | Content |
---|---|
F1 | The option to purchase 36,007 shares was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter. |
F2 | The option to purchase 31,138 shares was granted on March 5, 2020. The shares underlying the option vest over four years, with 25% of the shares vested on March 5, 2021 and the remaining shares vesting in equal quarterly installments thereafter. |
F3 | The option to purchase 31,138 shares was granted on March 5, 2020. The shares underlying the option vest in full upon the date on which the Board of Directors of the Issuer determines that the Issuer has dosed the initial patient in its first clinical trial, provided that such event occurs on or before July 1, 2023. |
F4 | The option to purchase 22,000 shares was granted on January 22, 2021. The shares underlying the option vest over four years, with 25% of the shares vested on January 22, 2022 and the remaining shares vesting in equal quarterly installments thereafter. |
F5 | The option to purchase 5,500 shares was granted on April 1, 2021. The shares underlying the option vest over two years, with 25% of the shares vested on October 1, 2021 and the remaining shares vesting in equal quarterly installments thereafter. |
F6 | The option to purchase 30,000 shares was granted on May 3, 2021. The shares underlying the option vest over four years, with 25% of the shares vested on May 3, 2022 and the remaining shares vesting in equal quarterly installments thereafter. |
F7 | The option to purchase 58,706 shares was granted on January 21, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on January 21, 2023 and the remaining shares vesting in equal quarterly installments thereafter. |
F8 | The grant of 33,000 restricted stock units was made on January 21, 2022. The shares underlying the restricted stock units vest over two years, with 25% of the shares vested on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. |
F9 | Each restricted stock unit represents the right to receive one share of the company's common stock. |